 |
市場調查報告書
商品編碼
1355800
膀胱癌市場:KOL的洞察Bladder Cancer - KOL Insight |
||||||
價格
簡介目錄
本報告提供全球膀胱癌市場相關調查，提供市場概要，以及已通過核准治療方法，開發平台趨勢，未來預測等資訊。
目錄
摘要整理
治療流程
調查目的
免疫療法
- 已上市治療方法
- Keytruda（pembrolizumab，默克公司）
- Opdivo（納武單抗，百時美施貴寶）
- Tecentriq（atezolizumab，羅氏）
- Bavencio（Avelumab，默克集團/輝瑞）
- 管道療法
- Imfinzi（durvalumab、阿斯特捷利康）
- Sasanlimab（輝瑞）
- Cetrelimab（楊森）
抗體-藥物結合物
- 市售治療方法
- Padocev（enfortumab vedotin，Astellas/Seagen）(9)
- Trodelvy（sacituzumab govitecan，吉利德）(12)
纖維母細胞生長因子受體 (FGFR) 抑制劑
- 市售治療方法
- Balversa（erdafitinib、楊森）
酪胺酸激?抑制劑
- 管道療法
- Cabometyx（卡博替尼、Exelixis/Ipsen）
其他作用機轉
- 市售治療方法
- Adostiladrine（nadofaragenfiladenovec，FKD Therapies/Ferring Pharmaceuticals）
- 管道療法
- Anctiva（N-803，ImmunityBio）
- CG0070（cletostimogen grenadenorepvec，CG 腫瘤學）
- Ruvidal（TLD-1433，Theralase）
未來的治療範例
- 主要見解摘要 (7)
- 用於更好地選擇患者的生物標記仍然是膀胱癌中未滿足的重要需求
附錄
KOL突發新聞
簡介目錄
While Merck & Co Keytruda + Astellas/Seagen's Padcev forges ahead, how do KOLs see the prospects of Keytruda + Taiho Pharmaceutical's futibatinib combination? How do experts assess FKD Therapies/Ferring Pharmaceuticals much needed Adstiladrin? Could a combination therapy strategy reinvigorate AstraZeneca's Imfinzi? KOLs critically assess the prospects of launched and pipeline therapies.
In addition to the full report, licensed users have access to the Report Highlights slidedeck and the following KOL Bulletins via the Attachments area.
- 03 Oct 23 KOL Bulletin -- Views on the results of Phase III EV-302 trial of Keytruda and Padcev in bladder cancer
Table of Contents
Executive summary (3)
Treatment algorithm
Research objectives (5)
Immunotherapies (69)
- Marketed therapies (42)
- Keytruda (pembrolizumab; Merck & Co.) (13)
- Opdivo (nivolumab; Bristol Myers Squibb) (14)
- Tecentriq (atezolizumab; Roche) (6)
- Bavencio (avelumab; Merck Group/Pfizer) (9)
- Pipeline therapies (27)
- Imfinzi (durvalumab; AstraZeneca) (11)
- Sasanlimab (Pfizer) (8)
- Cetrelimab (Janssen) (8)
Antibody-drug conjugates (21)
- Marketed therapies (21)
- Padcev (enfortumab vedotin; Astellas/Seagen) (9)
- Trodelvy (sacituzumab govitecan; Gilead) (12)
Fibroblast growth factor receptor (FGFR) inhibitors (9)
- Marketed therapies (9)
- Balversa (erdafitinib; Janssen) (9)
Tyrosine kinase inhibitors (7)
- Pipeline therapies (7)
- Cabometyx (cabozantinib; Exelixis/Ipsen) (7)
Other modes of action (34)
- Marketed therapies (11)
- Adstiladrin (nadofaragene firadenovec; FKD Therapies/Ferring Pharmaceuticals) (11)
- Pipeline therapies (23)
- Anktiva (N-803; ImmunityBio) (10)
- CG0070 (cretostimogene grenadenorepvec; CG Oncology) (6)
- Ruvidar (TLD-1433; Theralase) (7)
Future treatment paradigm (7)
- Key insights summary (7)
- Biomarkers for better patient selection remain an important unmet need in bladder cancer (5)
Appendix (3)
- KOL details (3)
- KOLs from North America (1)
- KOLs from Europe (1)
